Latency-Associated Nuclear Antigen Encoded by Kaposi's Sarcoma-Associated Herpesvirus Interacts with Tat and Activates the Long Terminal Repeat of Human Immunodeficiency Virus Type 1 in Human Cells

ABSTRACT The latency-associated nuclear antigen (LANA) is constitutively expressed in cells infected with the Kaposi's sarcoma (KS) herpesvirus (KSHV), also referred to as human herpesvirus 8. KSHV is tightly associated with body cavity-based lymphomas (BCBLs) in immunocompromised patients infected with human immunodeficiency virus (HIV). LANA, encoded by open reading frame 73 of KSHV, is one of a small subset of proteins expressed during latent infection and was shown to be important in tethering the viral episome to host chromosomes. Additionally, it has been shown that LANA can function as a regulator of transcription. However, its role in the progression of disease is still being elucidated. Since KS is one of the most common AIDS-associated cancers in the United States and BCBLs appear predominantly in AIDS patients, we examined whether LANA is able to regulate the HIV type 1 (HIV-1) long terminal repeat (LTR). Using luciferase-based transient transfection assays, we found that LANA was able to transactivate the HIV-1 LTR in the human B-cell line BJAB, human monocytic cell line U937, and the human embryonic kidney fibroblast cell line 293T. Moreover, we observed that the virus-encoded HIV transactivator protein Tat cooperated with LANA in activation of the LTR in a dose-response fashion with increasing amounts of LANA. Surprisingly, LANA alone was sufficient to transactivate the HIV-1 LTR in BJAB cells. In similar assays using a HIV-1 LTR construct with the core enhancer elements deleted; the activity of LANA was diminished but not abolished, indicating a mechanism which involves the cooperation of the core enhancer elements and downstream elements which include Tat. Furthermore, transient transfection of an infectious clone of HIV with LANA demonstrated effects similar to those seen in the reporter assays based on Western blot analysis of HIV Gag polypeptide p24. Interestingly, we also demonstrated that the carboxy terminus of LANA associates with Tat in cells and in vitro. These experiments suggest a role for LANA in activating the HIV-1 LTR through association with cellular molecules targeting the core enhancer elements and Tat and may have important consequences in increasing the levels of HIV in infected individuals and, hence, the disease state.

[1]  T. Piolot,et al.  Close but Distinct Regions of Human Herpesvirus 8 Latency-Associated Nuclear Antigen 1 Are Responsible for Nuclear Targeting and Binding to Human Mitotic Chromosomes , 2001, Journal of Virology.

[2]  M. Ballestas,et al.  Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen 1 Mediates Episome Persistence through cis-Acting Terminal Repeat (TR) Sequence and Specifically Binds TR DNA , 2001, Journal of Virology.

[3]  W. Hammerschmidt,et al.  Spontaneous Activation of the Lytic Cycle in Cells Infected with a Recombinant Kaposi's Sarcoma-Associated Virus , 2001, Journal of Virology.

[4]  E. Robertson,et al.  Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: A molecular link to cancer metastasis , 2001, Nature Medicine.

[5]  P. Brown,et al.  Modulation of Cellular and Viral Gene Expression by the Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus , 2001, Journal of Virology.

[6]  C. Lim,et al.  Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) binds ATF4/CREB2 and inhibits its transcriptional activation activity. , 2000, The Journal of general virology.

[7]  A. Krithivas,et al.  Human Herpesvirus 8 LANA Interacts with Proteins of the mSin3 Corepressor Complex and Negatively Regulates Epstein-Barr Virus Gene Expression in Dually Infected PEL Cells , 2000, Journal of Virology.

[8]  C. Boshoff,et al.  The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma–E2F pathway and with the oncogene Hras transforms primary rat cells , 2000, Nature Medicine.

[9]  S. Mahajan,et al.  Carboxy Terminus of Human Herpesvirus 8 Latency-Associated Nuclear Antigen Mediates Dimerization, Transcriptional Repression, and Targeting to Nuclear Bodies , 2000, Journal of Virology.

[10]  E. Robertson,et al.  Modulation of Histone Acetyltransferase Activity through Interaction of Epstein-Barr Nuclear Antigen 3C with Prothymosin Alpha , 2000, Molecular and Cellular Biology.

[11]  P. Brennan,et al.  Seroprevalence of Kaposi's sarcoma-associated herpesvirus in healthy adults in Israel. , 2000, Anticancer research.

[12]  M. Churchill,et al.  A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. , 2000, Nucleic acids research.

[13]  G. Nabel,et al.  p53 inhibition by the LANA protein of KSHV protects against cell death , 1999, Nature.

[14]  T. Schulz,et al.  Latent Nuclear Antigen of Kaposi’s Sarcoma-Associated Herpesvirus Interacts with RING3, a Homolog of theDrosophila Female Sterile Homeotic (fsh) Gene , 1999, Journal of Virology.

[15]  E. Robertson,et al.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. , 1999, Virology.

[16]  R. Edwards,et al.  HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches. , 1999, Biochemical pharmacology.

[17]  E. Robertson,et al.  Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection. , 1999, Virology.

[18]  P. Monini,et al.  Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. , 1999, Blood.

[19]  P. Brennan,et al.  Classic Kaposi's sarcoma as a second primary neoplasm , 1999, International journal of cancer.

[20]  G. Nabel,et al.  Interaction of Human Immunodeficiency Virus Type 1 Tat with the Transcriptional Coactivators p300 and CREB Binding Protein , 1998, Journal of Virology.

[21]  D. Ganem,et al.  Limited Transmission of Kaposi’s Sarcoma-Associated Herpesvirus in Cultured Cells , 1998, Journal of Virology.

[22]  W. Rozenbaum,et al.  Production of HIV-1 by human B cells infected in vitro: characterization of an EBV genome-negative B cell line chronically synthetizing a low level of HIV-1 after infection. , 1998, Virology.

[23]  D. Ganem,et al.  Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. , 1997, The Journal of clinical investigation.

[24]  B. Haar,et al.  Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8 , 1997, Journal of virology.

[25]  E. Kieff,et al.  Oncogenic Forms of NOTCH1 Lacking Either the Primary Binding Site for RBP-Jκ or Nuclear Localization Sequences Retain the Ability to Associate with RBP-Jκ and Activate Transcription* , 1997, The Journal of Biological Chemistry.

[26]  E. Cesarman,et al.  Kaposi's sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. , 1997, Seminars in diagnostic pathology.

[27]  G. Nabel,et al.  Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma. , 1997, The New England journal of medicine.

[28]  P. Simmonds,et al.  Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen , 1996, The Lancet.

[29]  E. Cesarman,et al.  Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. , 1996, Blood.

[30]  R. Biggar,et al.  The epidemiology of AIDS--related neoplasms. , 1996, Hematology/oncology clinics of North America.

[31]  E. Operskalski,et al.  The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma–associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission , 1996, Nature Medicine.

[32]  J. Phair,et al.  KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma , 1996, Nature Medicine.

[33]  E. Cesarman,et al.  Kaposi's sarcoma-associated herpesvirus in non-AIDS related lymphomas occurring in body cavities. , 1996, The American journal of pathology.

[34]  W. Zhong,et al.  Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  E. Cesarman,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. , 1995, The New England journal of medicine.

[36]  H. Gendelman,et al.  Efficient synthesis of viral nucleic acids following monocyte infection by HIV-1. , 1995, Virology.

[37]  G. Nabel,et al.  An interaction between the DNA-binding domains of RelA(p65) and Sp1 mediates human immunodeficiency virus gene activation , 1994, Molecular and cellular biology.

[38]  V. Zachar,et al.  Basal and Tat-transactivated expression from the human immunodeficiency virus type 1 long terminal repeat in human placental trophoblast rules out promoter-enhancer activation as the partial block to viral replication. , 1994, The Journal of general virology.

[39]  G. Nabel,et al.  A cooperative interaction between NF‐kappa B and Sp1 is required for HIV‐1 enhancer activation. , 1993, The EMBO journal.

[40]  P. Wingfield,et al.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation , 1993, Journal of virology.

[41]  P. Sharp,et al.  Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation , 1992, Journal of virology.

[42]  J. Kappes,et al.  Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes , 1991, Journal of virology.

[43]  V. Beral,et al.  Sexual spread of Kaposi's. , 1991, Nursing times.

[44]  B. Berkhout,et al.  trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis , 1989, Journal of virology.

[45]  B. Berkhout,et al.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target , 1989, Cell.

[46]  J. Karn,et al.  Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Tjian,et al.  Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. , 1986, Science.

[48]  E. Robertson,et al.  OF KAPOSI ’ S SARCOMA-ASSOCIATED HERPESVIRUS , 2002 .

[49]  K. Roebuck,et al.  Regulation of HIV-1 transcription. , 1999, Gene expression.

[50]  V. Beral The epidemiology of cancer in AIDS patients. , 1991, AIDS.

[51]  M. Hutt The epidemiology of Kaposi's sarcoma. , 1981, Antibiotics and chemotherapy.